Our findings suggest that initial screening with diagnostic immunohistochemistry for lung adenocarcinomas, followed by targeted PCR-based assays for common HER2 exon 20 insertions in non-smoking patients with wild-type EGFR/ALK status, could represent a cost-effective algorithm. The gene discussed is EGFR; the disease is lung adenocarcinoma.